Copy Link Print Information

オラパリブ

(別名: Olaparib; AZD-2281; KU-0059436)
375 Cited Publications
カスタマーレビュー

Based on 375 publication(s) in Google Scholar

Olaparib (AZD2281; KU0059436) is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator. Olaparib cannot cross the intact blood-brain barrier (BBB).

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

  • 純度: 99.98%
  • CAS 番号: 763113-22-0
  • 分子式: C24H23FN4O3
  • 分子量:434.46
  • 保管条件:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 2 years , -20°C, 1 year
  • Olaparib Chemical Structure
    Olaparib 構造式
  • Experimental Validation Results for Olaparib
  • Experimental Validation Results for Olaparib
  • Experimental Validation Results for Olaparib
  • Experimental Validation Results for Olaparib
  • Experimental Validation Results for Olaparib
  • Experimental Validation Results for Olaparib
  • Experimental Validation Results for Olaparib
  • Experimental Validation Results for Olaparib
  • Experimental Validation Results for Olaparib
  • Experimental Validation Results for Olaparib
  • Experimental Validation Results for Olaparib
  • Experimental Validation Results for Olaparib
  • Experimental Validation Results for Olaparib
  • Experimental Validation Results for Olaparib
  • Experimental Validation Results for Olaparib
  • Experimental Validation Results for Olaparib
  • Experimental Validation Results for Olaparib
  • Experimental Validation Results for Olaparib
  • Experimental Validation Results for Olaparib
  • Experimental Validation Results for Olaparib
  • Experimental Validation Results for Olaparib
  • Experimental Validation Results for Olaparib
  • Experimental Validation Results for Olaparib
  • Experimental Validation Results for Olaparib
CAS 番号: 763113-22-0
容量
価格（税別）
在庫状況
数量
Amount: USD 0.00
Please select quantity
or
or

* アイテムを追加する前、数量をご選択ください

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Olaparib:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
最寄りの代理店をお探しください Your local distributor: Hycultec GmbHHycultec
  • 生物活性
  • 化学情報
  • 溶剤 & 溶解度
  • プロトコル
  • 純度とドキュメンテーション
  • 参考文献
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

MedChemExpress（MCE）の使用を引用している文献 Olaparib

More
Customer Validation & Images
Flow CytometryBio/Physico-chemical AssayWBRT-PCRCell Proliferation/Viability Assay2D/3D Cell Culture and DifferentiationIHCGel ElectrophoresisIF
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • Gel Electrophoresis
  • IF
  • RT-PCR
  • Cell Proliferation/Viability Assay
  • WB
  • Bio/Physico-chemical Assay
  • 2D/3D Cell Culture and Differentiation
  • Flow Cytometry
  • IHC
  • IHC
  • WB
  • WB
  • WB
  • IHC
  • WB
  • IHC
  • WB
  • WB
  • WB
  • Cell Proliferation/Viability Assay
  • WB

PARP アイソフォーム固有の製品をすべて表示

More
Keywords
MOQ
Minimum order quantity
100 mg

お問い合わせ 在庫あり

Other size
お問い合わせ
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress ログイン
Register
Sign in to MedChemExpress
新規会員登録

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Olaparib Chemical Structure
    Olaparib Chemical Structure
    1/16
  • 1/16

    Olaparib purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2024 Aug 2;14(8):1476-1495. [Abstract]

    Customer Validation
     Cell viability in control or BRCA1-reconstituted UWB1.289 cells treated with PARPi (olaparib or niraparib, 42 hours) and/or RSL3 (18 hours).

  • 1/16

    Olaparib purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2024 Aug 2;14(8):1476-1495. [Abstract]

    Customer Validation
     Cell viability in BRCA1-sgRNA–infected or control HS578T cells treated with olaparib (42 hours) and/or RSL3 (18 hours).

  • 1/16

    Olaparib purchased from MedChemExpress. Usage Cited in: Drug Resist Updat. 2024 Sep 12:77:101151. [Abstract]

    Customer Validation
     Olaparib (1-3 μM) significantly inhibits the viability of sensitive cells (A2780) but exhibits reduced efficacy against resistant cells (A2780-OlaR), with IC50 values of 5.362 μM and 168.251 μM, respectively, for A2780 and A2780-OlaR cells.

  • 1/16

    Olaparib purchased from MedChemExpress. Usage Cited in: Drug Resist Updat. 2024 Sep 12:77:101151. [Abstract]

    Customer Validation
     Olaparib (10 μM) significantly induces DNA damage in sensitive cells (A2780).

  • 1/16

    Olaparib purchased from MedChemExpress. Usage Cited in: Drug Resist Updat. 2024 Sep 12:77:101151. [Abstract]

    Customer Validation
     Olaparib (10 μM; 2-4 h) significantly induces DNA damage in sensitive cells (A2780).

  • 1/16

    Olaparib purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2023 May 10;8(1):183. [Abstract]

    Customer Validation
     Cells were treated with indicated concentrations of olaparib (50-200 μM) for 6 h, and the levels of 47 S pre-rRNA were determined by qRT-PCR to assess the extent of ribosomal stress.

  • 1/16

    Olaparib purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2023 May 10;8(1):183. [Abstract]

    Customer Validation
     Cell viability assay was performed for Olaparib treated ovarian cancer organoids with/without pretreatment with the listed drugs.

  • 1/16

    Olaparib purchased from MedChemExpress. Usage Cited in: Nucleic Acids Res. 2023 Dec 11;51(22):12242-12260. [Abstract]

    Customer Validation
     Dot blot analysis of telomere DNA contents in the indicated ChIP and input from U2OS cells treated with either 1 μM Olaparib (OLP) or 2 μM STL127705 (STL) for 24 h.

  • 1/16

    Olaparib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2022 Nov:57:102507. [Abstract]

    Customer Validation
     MitoParaquat (0.1 μM, 30 min) abolished the inhibition of platelet aggregation by nicotinamide riboside (1 mM, 30 min) or olaparib (20 μM, 30 min) in resting platelets from LST patients.

  • 1/16

    Olaparib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2022 Nov:57:102507. [Abstract]

    Customer Validation
     MitoParaquat (0.1 μM, 30 min) did not interrupt the improvements in mitochondrial respiration induced by nicotinamide riboside (1 mM) or olaparib (20 μM) in resting platelets from LST patients.

  • 1/16

    Olaparib purchased from MedChemExpress. Usage Cited in: Cell Rep. 2022 Oct 11;41(2):111462. [Abstract]

    Customer Validation
     With an alternative ROS scavenger, the vitamin E analog Trolox, Olaparib-induced ROS production was similarly suppressed

  • 1/16

    Olaparib purchased from MedChemExpress. Usage Cited in: J Biomed Sci. 2019 Feb 4;26(1):14.  [Abstract]

    Customer Validation
     Inhibition of NFBD1 results in defective γ-H2AX foci formation after Olaparib exposure, cells are exposed to Olaparib for 24 h, and the γ-H2AX positive cells are determined by FCM

  • 1/16

    Olaparib purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2019 May:43:225-237. [Abstract]

    Customer Validation
     Representative images of immunohistochemical staining for proteins as indicated in A2780 xenografted tumors (n=6 per treatment group) treated with Olaparib and PD 0332991 either as single-agents or in combination for 4 days.

  • 1/16

    Olaparib purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2019 Jun:44:419-430. [Abstract]

    Customer Validation
     Immunoblots (IB) are done to detect γH2AX and DNA repair proteins, Ku80 and RAD51 using UAB-PA4 or UAB-PA16 tumors harvested from mice 24 h following final treatment. Quantitation by densitometry of results is shown below each IB image.

  • 1/16

    Olaparib purchased from MedChemExpress. Usage Cited in: Mol Cancer Res. 2019 Jan;17(1):42-53. [Abstract]

    Customer Validation
     Combination of RAD001 with Olaparib (left panel) and AZD2014 with Olaparib (right panel) activates the RIPK1 Ser 166 phosphorylation in Clone A and SF-539 cells respectively.

  • 1/16

    Olaparib purchased from MedChemExpress. Usage Cited in: Gynecol Oncol. 2019 Jan;152(1):157-165. [Abstract]

    Customer Validation
     The expression of CCND1mRNA and cyclin D1 protein level in A2780 and SKOV3 cells is analyzed by western blot after Olaparib treatment at IC50 concentrations.

  • 1/16

    Olaparib purchased from MedChemExpress. Usage Cited in: Gynecol Oncol. 2019 Jan;152(1):157-165. [Abstract]

    Customer Validation
     Immunohistochemistry for CCND1 is performed in tumor samples in the treatment of compounds (control, scrambled shRNA treated, Olaparib + scrambled shRNA treated, or Olaparib + CCND1-shRNA treated).

  • 1/16

    Olaparib purchased from MedChemExpress. Usage Cited in: Gynecol Oncol. 2019 Jan;152(1):157-165. [Abstract]

    Customer Validation
     CCDN1 protein level in tumor samples of different treatment groups (control, scrambled shRNA treated, Olaparib + scrambled shRNA treated, or Olaparib + CCND1-shRNA treated) are analyzed by western blot.

  • 1/16

    Olaparib purchased from MedChemExpress. Usage Cited in: Gynecol Oncol. 2019 Jan;152(1):157-165. [Abstract]

    Customer Validation
     Immunohistochemistry of RAD51 and γ-H2AX in samples of SKOV3 tumors. Representative sections are taken from tumor tissue of control, scrambled shRNA treated, Olaparib + scrambled shRNA treated, or Olaparib + CCND1-shRNA treated mice.

  • 1/16

    Olaparib purchased from MedChemExpress. Usage Cited in: Oncogene. 2018 Jan 18;37(3):341-351. [Abstract]

    Customer Validation
     PTEN-deficient endometrioid endometrial cancer cell lines are treated with drugs as indicated for 24 h. Phosphorylated AKT, S6RP and 4EBP1 proteins and cleaved PARP are detected by western blot. Vinculin served as a loading control.

  • 1/16

    Olaparib purchased from MedChemExpress. Usage Cited in: Mol Cancer Ther. 2018 Dec;17(12):2676-2688. [Abstract]

    Customer Validation
     EW8 and TC71 cells are treated with Olaparib (5 μM) or U0126 (5 μM) for 24 hours and then protein synthesis is assessed using puromycin labeling.

  • 1/16

    Olaparib purchased from MedChemExpress. Usage Cited in: Oncol Rep. 2018 Apr;39(4):1747-1756. [Abstract]

    Customer Validation
     The effect of Olaparib on protein expression. Western blot assays of MUS81 and MCM2 expression levels in A2780 and SKOV3 cells after treatment with 5 μM Olaparib compared with a blank control.

  • 1/16

    Olaparib purchased from MedChemExpress. Usage Cited in: Cancer Chemother Pharmacol. 2017 Oct;80(4):861-867. [Abstract]

    Customer Validation
     PARP1 inhibition is lethal to MPM cells. Colony formation assays of clonal cell survival with continuous Niraparib or Olaparib, both at 3 uM. a H2452 BPA1-mutant MPM cells exposed to Niraparib. b HMeso01A BAP1-mutant MPM cells exposed to Niraparib. cHMeso01A BAP1-mutant MPM cells exposed to Olaparib. d CRL-2081 BAP1 wild-type MPM cells exposed to Olaparib. e CRL-2081 BAP1 wild-type MPM cells exposed to Niraparib. f Dose response of H2452 BPA1-mutant MPM cells exposed to varying concentrations of

  • 1/16

    Olaparib purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2016 Feb 24;17(3):272. [Abstract]

    Customer Validation
     The effect of AZD2281 on the protein expression of xenografted HSC-2 tumors. Relative band intensity of western blot data is normalized by the expression level of β-actin; The proteins analyzed are PARP-1 (poly(ADP-ribose) polymerase-1).

  • Olaparib